Nitto-denko Corporation

Epigen Biosciences, Inc.

Hiep Luu

Chandravadan R Shah

Sazzadur Rahman Khan

Fabio C Tucci

Graham Beaton

Satheesh Babu Ravula

Ekambaram Sambandan

Satheesh B Ravula

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

Heterocyclic compounds useful in the treatment of disease

Described herein are liquid crystal compositions containing a five-member heterocyclic ring that can allow for the adjustment of their refractive indices under the application of an electric field. In addition, selectively dimmable reverse-mode polymer dispersed liquid crystal elements and devices using the aforementioned compositions are also described, which are transparent when no voltage is applied and opaque when a voltage is applied.

Liquid crystal composition containing a five-membered heterocyclic ring, reverse-mode polymer dispersed liquid crystal element, and associated selectively dimmable device

Heterocyclic liquid crystal compositions that can allow for the adjustment of their refractive indices by the application of an electric field, such as those described by the following formula: are disclosed. Also disclosed are selectively dimmable reverse-mode polymer dispersed liquid crystal (PDLC) elements and devices using the aforementioned compositions, which are transparent when no voltage is applied and opaque when a voltage is applied.

Heterocyclic liquid crystal composition, reverse-mode polymer dispersed liquid crystal element, and associated selectively dimmable device

Described herein are heterocyclic liquid crystal compositions that can allow for the adjustment of their refractive indices by the application of an electric field. In addition, selectively dimmable reverse-mode polymer dispersed liquid crystal (PDLC) elements and devices using these compositions are also described, which are transparent when no voltage is applied and opaque when a voltage is applied.

Heterocyclic liquid crystal composition, reverse-mode polymer dispersed liquid crystal element, and selectively dimmable device

Described herein are liquid crystal compositions and derivative mixtures thereof that can allow for the adjustment of their refractive indices by the application of an electric field. In addition, selectively dimmable reverse-mode polymer dispersed liquid crystal (PDLC) elements and devices using the aforementioned compositions are also described, which are transparent when no voltage is applied and opaque when a voltage is applied.

Liquid crystal composition, liquid crystal mixture, reverse-mode polymer dispersed liquid crystal element, and associated selectively dimmable device

A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Growing community of inventors

San Marcos, CA, United States of America

Hiep Luu